Menu Search
Equities

Consun Pharmaceutical Group Ltd

CPHGF:PKC

Consun Pharmaceutical Group Ltd

Actions
  • Price (USD)0.00
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Dec 30 1899.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Consun Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The pharmaceutical products of the Company include kidney medicines, contrast medium and others. The Company’s subsidiaries include Brilliant Reach Group Limited, Century International Develop Limited and Grand Reach Company Limited. Through its subsidiaries, the Company is also engaged in the research and development of pharmaceutical products.

  • Revenue in HKD (TTM)2.80bn
  • Net income in HKD848.72m
  • Incorporated2010
  • Employees3.13k
  • Location
    Consun Pharmaceutical Group Ltd71 Dongpeng Avenue, East SectionEconomic and Technological DevelopmentGuangzhou Luogang DistrictGUANGZHOU 510760ChinaCHN
  • Phone+86 2 082016888
  • Fax+86 2 082017468
  • Websitehttp://www.chinaconsun.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.